New post hoc and pooled analyses from the OASIS 4 trial presented at ObesityWeek 2025 show that oral semaglutide 25 mg improves glycemic control, cardiovascular risk factors, and weight outcomes ...

ORLANDO -- Long-term results from trials of new drugs for hereditary angioedema (HAE) continue to support efficacy and safety ...

Imneskibart will now enter late-stage trials after the drug offered durable tumour shrinkage in NSCLC, melanoma and other ...

Developed by British drugmaker GSK, RTS,S/AS01E in 2021 became the first malaria vaccine to be recommended by the World ...

Akebia Therapeutics shares retreated Monday after the company dropped plans for a Phase 3 clinical trial of its drug Vafseo for certain patients. Shares were trading at $1.66, down 19% and nearing the ...

Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...

D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all ...

Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

An update from Psyence Biomedical ( ($PBM) ) is now available. Psyence Biomedical Ltd. recently appointed its Chief Financial Officer, Mr. Warwick ...

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced third quarter 2025 financial results and provided ...